



## Dr. med. Ursula Hasler-Strub

### Contact

Dr. med. Ursula Hasler-Strub  
Rorschacherstrasse 95  
9007 St.Gallen  
Switzerland

T +41 71 494 19 32  
ursula.hasler-strub@kssg.ch

### Homepage

[www.kssg.ch/brustzentrum](http://www.kssg.ch/brustzentrum)

### Units

Medizinische Onkologie und Hämatologie, Brustzentrum St.Gallen

### Profile Function

chief of service

## Publications (5)

Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. *Ann Oncol* 2017

Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. *BMC cancer* 2016; 16:780.

Zaman K, Rondeau S, Hawle H, Rudolf C, Perey L, Wiliders H, Berset C, Mueller A, Rochlitz C, Hasler-Strub U, Mamot C, Winterhalder R, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. *Eur J Cancer* 2015; 51:1212-20.

Hasler-Strub U, Moos R. [Breast cancer: screening, treatment and follow-up]. *Praxis (Bern 1994)* 2010; 99:413-8.

Hess B, Hasler-Strub U, Ackermann D, Jaeger P. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. *Nephrol Dial Transplant* 1997; 12:1362-8.

## Projects (10)

**Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial**

*Clinical Studies - Mar 4, 2021 - Dec 24, 2025*

*Ongoing*

**SAKK 21/18 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A mul-ticenter, randomized phase III trial**

*Clinical Studies - Jun 25, 2019 - Dec 31, 2026*

*Ongoing*

**Eribulin as 1st line treatment in elderly patients ( $\geq 70$  years) with advanced breast cancer: a multicenter phase II trial**

*Clinical Studies - Aug 11, 2015 - Jun 30, 2019*

*Automatically Closed*

**Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progress-ing within 6-12 months of last platinum**

*Clinical Studies - Jul 4, 2014 - Apr 16, 2021*

*Automatically Closed*

**A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Plati-num sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line**

*Clinical Studies - May 27, 2014 - Jun 27, 2016*

*Automatically Closed*

**A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer**

*Clinical Studies - Oct 21, 2013 - Apr 30, 2016*

*Completed*

**A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer**

*Clinical Studies - May 1, 2013 - May 1, 2019*

*Automatically Closed*

**SAKK 22/10: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in pa-tients with HER2-positive metastatic breast cancer**

*Clinical Studies - Apr 29, 2013 - Jun 27, 2015*

*Automatically Closed*

**Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) ½ inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: A randomized placebo-controlled double-blind phase II trial**

*Clinical Studies - Dec 7, 2010 - Dec 31, 2012*

*Completed*

**Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial**

*Clinical Studies - Jul 23, 2010 - Sep 30, 2013*

*Automatically Closed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch